TTK Healthcare Ltd.

TTK Healthcare has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. The stock’s recent price movements and technical parameters suggest a cautious market stance amid broader sectoral and index trends.

TTK Healthcare has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. The changes stem from a combination of factors including valuation appeal, subdued financial momentum, and technical indicators, set against a backdrop of underwhelming stock performance over the past year.

TTK Healthcare Ltd. commenced trading today with a notable gap up, opening at Rs 1179.95, marking a 6.39% rise from its previous close. This significant jump outpaced the broader Sensex, which recorded a marginal gain of 0.11%, signalling a robust start for the diversified sector stock.

TTK Healthcare . commenced trading today with a notable gap up, opening at Rs 1,194.95, marking a 6.35% rise from its previous close. This strong start underscores a positive market response amid a backdrop of sustained momentum over recent sessions.

TTK Healthcare has experienced a notable shift in its technical momentum, with recent evaluation adjustments reflecting a predominantly bearish outlook across multiple timeframes. The stock’s price action, combined with key technical indicators such as MACD, RSI, and moving averages, suggests a complex market assessment that investors should carefully consider amid broader sector and market trends.

TTK Healthcare has recently revised its evaluation amid changing market conditions. The stock is currently priced at 1,145.15, with mixed technical signals indicating caution. While it has underperformed the Sensex over the past year, its five-year return significantly surpasses the index, suggesting potential for future recovery.

TTK Healthcare has recently revised its evaluation amid changing market conditions. The stock price has decreased, with mixed technical indicators reflecting varying trends. While the company has struggled in the short term compared to the Sensex, it has demonstrated significant long-term resilience over five years.

TTK Healthcare has recently revised its evaluation amid changing market conditions. The stock has faced a challenging year with a return of -21.13%, contrasting with the Sensex's gain. Technical indicators show mixed signals, while the company has experienced notable fluctuations in stock performance over various timeframes.

TTK Healthcare has recently revised its stock evaluation amid fluctuating market conditions. Currently priced at 1,149.05, the stock has experienced mixed technical indicators and underperformed against the Sensex in the short term, while showing stronger long-term returns over five years. The company's market position reflects ongoing challenges.

TTK Healthcare Ltd., the Chennai-based pharmaceuticals company renowned for its Woodwards Gripewater brand, reported a net profit of ₹20.39 crores for Q2 FY26 (July-September 2025), marking an 18.56% quarter-on-quarter increase from ₹13.00 crores in Q1 FY26. However, the year-on-year comparison reveals a modest 3.17% decline from ₹17.20 crores in Q2 FY25, raising concerns about the quality and sustainability of the company's earnings growth.

TTK Healthcare saw a significant increase on October 17, 2025, despite underperforming its sector. The stock's trading has been erratic, with several days of inactivity. Currently, it is trading below key moving averages, indicating a challenging trend, while the broader market shows resilience and bullish sentiment.